Latest / This Week In Medicine / 7 21 2025

Transcript

7 21 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Perioperative Dervalamab in Gastric and Gastrosophageal Junction Cancer.
• 0:44
  [SPEAKER_01]: Background.
• 0:45
  [SPEAKER_01]: Perioperative Flot.
• 0:47
  [SPEAKER_01]: Flororicill, Luca Vorin, Oxali Platon, and Dosataxyl is a standard therapy for resectable gastric and gastrosophageal junction at anocarsinomas, but recurrence rates remain high.
• 1:00
  [SPEAKER_01]: Amunotherapy plus chemotherapy may improve outcomes dot conclusions.
• 1:05
  [SPEAKER_01]: Perioperative Dervalema plus flot led to significantly better event-free survival outcomes than flot alone among participants with resectable gastric or gastrosophageal junction at an Ocarcinoma.
• 1:23
  [SPEAKER_01]: Next article.
• 1:24
  [SPEAKER_01]: First line treatment of pulmonary sarcoidosis with prednesone or methotrexate.
• 1:30
  [SPEAKER_01]: Background.
• 1:31
  [SPEAKER_01]: Prednesone is currently recommended as the first line treatment for pulmonary sarcoidosis, but is associated with many side effects.
• 1:38
  [SPEAKER_01]: Methotrexate, which is recommended as a second line treatment, appears to have fewer side effects than prednesone but a slower onset of action.
• 1:47
  [SPEAKER_01]: Data are needed on the efficacy and side effect profile of Methotrexate as compared with prednesone as first line treatment for pulmonary sarcoidosis-psychoclutions.
• 1:57
  [SPEAKER_01]: In patients with pulmonary sarcoidosis, initial treatment with methyltrexate was not inferior to that with prednesone with regard to the change from baseline to week twenty-four in the percentage of the predicted FEC.
• 2:10
  [SPEAKER_01]: Differences in the side effect profile between methyltrexate and prednesone may inform shared decision-making by providers and patients about the appropriate treatment approach.
• 2:20
  [SPEAKER_01]: Next article, graphed versus host disease prophylaxis with cyclophosphamide and cyclosporin.
• 2:27
  [SPEAKER_01]: Background Allogeneic peripheral blood stem cell transplantation, SCT, from a matched related donor after myelooblative conditioning, is the preferred curative treatment for patients with high-risk blood cancers.
• 2:40
  [SPEAKER_01]: The combination of a calcinerine inhibitor and an anti-metabolite remains standard care for graft versus host disease, GVHD, Prophylaxis in these patients.
• 2:50
  [SPEAKER_01]: Data from two randomized trials have suggested that post-transplantation cyclophosphamide can reduce the risk of GVHD after SET from a match donor when it is added to or replaces the anti-metabolite.
• 3:04
  [SPEAKER_01]: However,
• 3:05
  [SPEAKER_01]: The effects of post-transplantation cyclophosphomide specifically after SCT from a matched related donor remain uncertain, and effects in the context of myelo-applative conditioning are unclear to see-onge conclusions.
• 3:18
  [SPEAKER_01]: The combination of post-transplantation cyclophosphomide and a calcinerine inhibitor led to longer GVHD-free, relapse-free survival than standard profile axis after transplantation from a matched related donor.
• 3:31
  [SPEAKER_01]: with either reduced intensity or mylo-applative conditioning in patients with blood cancers.
• 3:42
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 3:47
  [SPEAKER_01]: Hepatitis C screening in emergency departments.
• 3:50
  [SPEAKER_01]: The detect Hep C randomized clinical trial.
• 3:53
  [SPEAKER_01]: Question, what is the most effective way to screen patients for hepatitis C virus, HCV, infection in emergency departments, ads, findings?
• 4:03
  [SPEAKER_01]: This multisenter randomized clinical trial included
• 4:10
  [SPEAKER_01]: Of these, seventy-three-eight hundred forty-seven underwent non-targeted screening, resulting in nine thousand-eight hundred sixty-seven tested for HCV and one hundred fifty-four new diagnoses, whereas seventy-three-six hundred fifty-one underwent targeted HCV screening, resulting in four thousand-six hundred forty-tested for HCV and one hundred fifteen new diagnoses.
• 4:33
  [SPEAKER_01]: Compared with targeted HCV screening, non-targeted screening was associated with significantly higher numbers of new HCV diagnoses.
• 4:41
  [SPEAKER_01]: Relative risk, one point three four, ninety five percent C, one point zero five to one point seven zero.
• 4:48
  [SPEAKER_01]: P equals point zero two.
• 4:50
  [SPEAKER_01]: Meaning non-targeted HCV screening was superior to targeted screening for identifying HCV infection in the ED.
• 5:03
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 5:07
  [SPEAKER_01]: Vaporized nicotine products for smoking cessation among.
• 5:11
  [SPEAKER_01]: Background.
• 5:12
  [SPEAKER_01]: Vaporized nicotine products, VNPs, are more effective than nicotine replacement therapy, NRT, for smoking cessation in general populations, but their effectiveness among low socioeconomic groups is largely unknown dot objective.
• 5:27
  [SPEAKER_01]: To examine whether VNPs are more effective than NRT for smoking cessation among people experiencing social disadvantage, conclusion.
• 5:36
  [SPEAKER_01]: Findings indicate that VNPs were more effective than NRT for smoking cessation in this population.
• 5:42
  [SPEAKER_01]: Given the challenges for cessation among these socially disadvantaged populations, VNPs present a promising treatment option for this priority group.
• 5:57
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 6:00
  [SPEAKER_01]: Global, regional, and national characteristics of the main causes of increased disease burden due to the COVID-nineteen pandemic.
• 6:08
  [SPEAKER_01]: Objective.
• 6:10
  [SPEAKER_01]: To quantify and identify the main causes of increased disease burden due to coronavirus disease, COVID-nineteen, pandemic conclusion.
• 6:19
  [SPEAKER_01]: The COVID-nineteen pandemic significantly increased the burden of several non-COVID conditions, particularly mental health disorders, malaria in young children in the African region, and stroke and eschemic heart disease in older adults, with notable disparities across age and sex.
• 6:35
  [SPEAKER_01]: These findings underscore the urgent need to strengthen health system resilience, enhance integrated surveillance, and adopt systemic informed strategies to support equitable preparedness for future public health emergencies.
• 6:54
  [SPEAKER_01]: Next we will be discussing articles from Lancet.
• 6:57
  [SPEAKER_01]: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-One and Amaline receptor agonist, Amacreaten, a first-in-human phase-one, double-blind, randomized, placebo-controlled trial.
• 7:12
  [SPEAKER_01]: Background
• 7:13
  [SPEAKER_01]: GLP-One receptor agonists and Amaline receptor agonists have shown clinically relevant weight loss and glucose lowering effects in people with overweight, obesity and type two diabetes.
• 7:25
  [SPEAKER_01]: Amacreatin is a novel, single molecule GLP-One receptor and Amaline receptor agonist.
• 7:31
  [SPEAKER_01]: We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses, part A and multiple ascending doses, parts B and CD of a microtin in adult participants with overweight or obesity interpretation.
• 7:50
  [SPEAKER_01]: In people with overweight or obesity, a Macreaton appeared safe and tolerable.
• 7:54
  [SPEAKER_01]: Results from this first-in-human phase-one study support further investigation of the weight loss properties of Omicreaton.
• 8:08
  [SPEAKER_01]: Next we will be discussing articles in the field of hematoconcology.
• 8:12
  [SPEAKER_01]: Here are the articles from Journal of Clinical Oncology.
• 8:15
  [SPEAKER_01]: A calibruteneb plus bend a mustine retoxamab in untreated mantle cell lymphoma.
• 8:21
  [SPEAKER_01]: Purpose.
• 8:22
  [SPEAKER_01]: The combination of the bruten tyrosine kinase inhibitor ibruteneb with bend a mustine retoxamab for first line treatment of mantle cell lymphoma.
• 8:30
  [SPEAKER_01]: MCL, prolonged progression free survival, PFS, but without improvement in overall survival OS, likely because of toxicity.
• 8:40
  [SPEAKER_01]: A calibrutinib was shown to be efficacious and less toxic than I brutinib, in a head-to-head trial in chronic lymphocytic leukemia, and therefore might lead to better outcomes in MCL conclusion.
• 8:51
  [SPEAKER_01]: The combination of a calibrate nib with Bendomustine Retoxamab significantly improved PFS.
• 8:57
  [SPEAKER_01]: Clinical benefit of a calibrate nib with Bendomustine Retoxamab was achieved with manageable toxicity.
• 9:10
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 9:14
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 9:17
  [SPEAKER_01]: Electroacupuncture reduces duration of postoperative illius.
• 9:21
  [SPEAKER_01]: After laparoscopic gastrectomy for gastric cancer, a multi-center randomized trial.
• 9:26
  [SPEAKER_01]: Background and aims.
• 9:28
  [SPEAKER_01]: Electroacupuncture, EA, may reduce the duration of postoperative illius, POI, after laparoscopic gastrectomy for gastric cancer, although evidence is limited.
• 9:39
  [SPEAKER_01]: We investigated the efficacy of EA in reducing POI duration and enhancing gastrointestinal GI recovery in patients undergoing laparoscopic surgery for gastric cancer dot conclusions.
• 9:51
  [SPEAKER_01]: EA was superior to SA and standard care, only for reducing POI duration and the risk of prolonged POI in patients undergoing laparoscopic gastrectomy for gastric cancer.
• 10:08
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 10:11
  [SPEAKER_01]: Budesanite versus misalamine in microscopic colitis, a comparative meta-analysis of randomized controlled trials.
• 10:19
  [SPEAKER_01]: Background.
• 10:20
  [SPEAKER_01]: Microscopic colitis MC is an inflammatory bowel disease of autoimmune origin that causes chronic watery diarrhea, medications, including budesanite, misalamine, laparamide, cholesterolamine, and bismuth subsalicilate are first-line therapies.
• 10:37
  [SPEAKER_01]: Meanwhile, as a thighoprene, six-micaptopuring, and methotrexate are indicated for refractory MC, objective.
• 10:46
  [SPEAKER_01]: We aim to assess the efficacy and safety of budesanite compared with misalamine for induction of remission in MC patients' tons conclusions.
• 10:54
  [SPEAKER_01]: Budesanite was found to be better than misalamine in MC patients in terms of clinical remission rate.
• 11:00
  [SPEAKER_01]: Especially after eight weeks of follow-up.
• 11:02
  [SPEAKER_01]: Budesanite also showed less incidents of adverse events.
• 11:05
  [SPEAKER_01]: There is an urgent need for randomized double-blinded clinical trials to provide direct and reliable evidence.
• 11:17
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 11:21
  [SPEAKER_01]: Here are the articles from circulation.
• 11:23
  [SPEAKER_01]: Pulse Field Ablation of persistent atrial fibrillation with continuous electrocardiographic monitoring follow-up, ADVantage AF Phase II.
• 11:33
  [SPEAKER_01]: Background There are sparse high-quality safety and effectiveness data for post-field ablation, PFA, of persistent atrial fibrillation, per AF, in which lesions beyond pulmonary vein isolation, PVI, are often placed.
• 11:49
  [SPEAKER_01]: In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after oblation in patients with per AF or after PFA in any atrial fibrillation population.
• 12:01
  [SPEAKER_01]: In Phase II of the Advantage AF study, a prospective single-arm open label study of the Faripulse Pulse Field Ablation System in subjects with persistent atrial fibrillation.
• 12:11
  [SPEAKER_01]: Patients with per AF underwent PFA for PVI and posterior wallablation, PWA, and in a subcohort, cavitricuspid ismysublation for typical atrialflutter.cinclusions.
• 12:26
  [SPEAKER_01]: In phase two of advantage AF, the first multi-center per AF study of PFA, with continuous rhythm monitoring, one, cavitricuspid ismysublation with nitroglycerin prophylaxis with safe and effective.
• 12:40
  [SPEAKER_01]: Two, PVI plus posterior wallablation was safe and effective.
• 12:44
  [SPEAKER_01]: And three, an AA burden less than zero point one percent, and AA episode less than one hour duration, were endpoints associated with the lowest health care use.
• 13:01
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology and Pact of Optical Coherence Demography-based Post-PCI Physiology Assessment to Predict Clinical Outcomes and Illumian Force Ups study.
• 13:13
  [SPEAKER_01]: Background.
• 13:14
  [SPEAKER_01]: A novel Optical Coherence Demography, OCT-based Physiology Assessment Technique, Virtual Flow Reserve, VFR, has been demonstrated to perform as a reliable circuit for invasive physiology conclusions.
• 13:27
  [SPEAKER_01]: Post-PCI OCT-based VFR assessment is predictive of two-year clinical outcomes independent of MSA.
• 13:35
  [SPEAKER_01]: Online VFR analysis can provide operators with an immediate assessment of post-PCI physiology, in addition to OCT anatomy, providing incremental value in assessing procedural success and informing on clinical prognosis.
• 13:55
  [SPEAKER_01]: from JAMA cardiology.
• 13:57
  [SPEAKER_01]: Emergency Department based education and M Health Empowerment Intervention for hypertension, the touched randomized clinical trial.
• 14:05
  [SPEAKER_01]: Question.
• 14:06
  [SPEAKER_01]: Does an education and M Health Empowerment E-II, intervention delivered by a multidisciplinary team to patients identified in the emergency department, ED?
• 14:15
  [SPEAKER_01]: With high systolic blood pressure, SPP lead to greater reductions in SPP at six months, findings.
• 14:22
  [SPEAKER_01]: In this randomized clinical trial, among five hundred seventy four patients with elevated BP enrolled from a single center ED, those randomized to the E-II intervention had greater reduction in SPP at six months, compared with those who received standard discharge care, meaning results, suggests that an ed-based E-II intervention may be effective in improving hypertension management,
• 14:44
  [SPEAKER_01]: Compared with standard discharge instructions without patient referral.
• 14:54
  [SPEAKER_01]: Next, we will be discussing articles in the field of endocrinology.
• 14:57
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 15:02
  [SPEAKER_01]: Clomaphine citrate medication for infertility and risk of stillbirth or neonatal death, a population-based cohort study.
• 15:10
  [SPEAKER_01]: Objective.
• 15:11
  [SPEAKER_01]: To assess associations between clomaphine citrate, CC, use and perinatal death.design.
• 15:18
  [SPEAKER_01]: Whole of population data linkage cohort conclusion.
• 15:22
  [SPEAKER_01]: Risk of perinatal death may be increased in pregnancies that follow use of CC, while established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying
• 15:40
  [SPEAKER_01]: Here are the articles from diabetes care.
• 15:43
  [SPEAKER_01]: Comparison of serum creatinine and cystatincy-based EEG fur at basaline, and their prediction of incident moderate albuminuria in individuals with type one diabetes.
• 15:54
  [SPEAKER_01]: Objective
• 15:55
  [SPEAKER_01]: To assess the concordance between serum creatinine, SCR, and serum sustatency, sysc, based estimated glomerular filtration rate, EEGFR, in individuals with type one diabetes, T-one D, at different stages of albuminuria.
• 16:11
  [SPEAKER_01]: Identify the factors associated with the discordance, and study the association of sysc, eGfer of creatinine, eGfercer, and eGfer of sustatency, eGferces of sustatency, eGferces
• 16:25
  [SPEAKER_01]: With incident moderate albuminuria, seek conclusions.
• 16:29
  [SPEAKER_01]: These findings suggest seismic may facilitate early identification of individuals at risk for albuminuria.
• 16:42
  [SPEAKER_01]: Next we will be discussing articles in the field of neurology.
• 16:45
  [SPEAKER_01]: Here are the articles from neurology.
• 17:18
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 17:22
  [SPEAKER_01]: Here are the articles from Chest.
• 17:24
  [SPEAKER_01]: Modified cuff leak test for predicting the risk of re-intubation and patients with invasive mechanical ventilation.
• 17:31
  [SPEAKER_01]: Background.
• 17:33
  [SPEAKER_01]: The cuff leak test, CLT,
• 17:35
  [SPEAKER_01]: is an important tool to assess the risk of upper airway obstruction after extubation.
• 17:40
  [SPEAKER_01]: Research question.
• 17:42
  [SPEAKER_01]: Does a modified CLT approach have superior ability in predicting re-intubation compared with the traditional method?
• 17:48
  [SPEAKER_01]: Interpretation.
• 17:50
  [SPEAKER_01]: Compared with the control group, the modified CLT approach might better predict pests within twenty-four hours of extubation, especially for patients with IMV duration longer than six days, but it was not shown to decrease the re-intubation incidence and mortality.
• 18:10
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 18:15
  [SPEAKER_01]: Airway scaffolds for emphysema related hyperinflation.
• 18:19
  [SPEAKER_01]: Six month results from the brief trial.
• 18:21
  [SPEAKER_01]: Rational, despite advancements in emphysema treatment, high morbidity and mortality rates highlight the need for innovative therapies.
• 18:29
  [SPEAKER_01]: A novel self-expanding knit-null airway scaffold was designed to alleviate lung hyperinflation by connecting emphysemitous perencoma with central bronchi, releasing trapped air, objectives to assess the feasibility, safety, and initial outcomes of airway scaffolds in treating emphysema-related hyperinflation.
• 18:49
  [SPEAKER_01]: Conclusions.
• 18:50
  [SPEAKER_01]: This study provides the first clinical evidence of the feasibility, safety, and initial outcomes after treatment with airway scaffolds and patients with infosema related hyperinflation.
• 19:06
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 19:09
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 19:14
  [SPEAKER_01]: The emerging nephrology physician workforce in the United States, defining an impending shortfall.
• 19:20
  [SPEAKER_01]: Key points.
• 19:21
  [SPEAKER_01]: Consistent growth in the number of nephrology fellowship programs and fellowship positions, along with a consistent decline in the number of applicants.
• 19:29
  [SPEAKER_01]: Approximately one-third of available nephrology fellowship training positions went unmatched.
• 19:34
  [SPEAKER_01]: The results from this study suggest that the bottleneck to increasing the future nephrologist workforce exists in recruiting interested applicants.
• 19:47
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 19:51
  [SPEAKER_01]: Point of care testing and integrated digital health technology for CKD screening in high-risk populations of India.
• 19:58
  [SPEAKER_01]: Introduction.
• 19:59
  [SPEAKER_01]: Chronic kidney disease, CKD, is a significant contributor to morbidity, mortality, and health care expenditure.
• 20:07
  [SPEAKER_01]: Lack of early diagnosis with treatment leads to progression to advanced stages requiring high-cost interventions.
• 20:13
  [SPEAKER_01]: The current pilot study examined the feasibility of using point of care testing, POCT, and digital health technology for CKD screening dot conclusion.
• 20:23
  [SPEAKER_01]: CKD screening using poct and digital health technology allowed diagnosis of CKD in patients of high-risk groups and should be scaled up with the final goal to ensure early diagnosis, decrease costs, and improve patient's clinical management.
• 20:38
  [SPEAKER_00]: Thank you for listening to this week in medicine.
• 20:40
  [SPEAKER_00]: Your filtered medical journal summary.
• 20:42
  [SPEAKER_00]: Have a great week ahead.
• 20:44
  [SPEAKER_00]: Stay blessed and be humane.